About McKesson Corp
- Industry: Health Care
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.mckesson.com/
Frequently Asked Questions
What is the 52-week range for MCK?
The 52-week high is $999 and the 52-week low is $723.68.
What is the P/E ratio for MCK?
The Price to Earnings (P/E) ratio is 22.62.
What is the dividend yield for MCK?
The indicated annual dividend yield is 0.54%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 39.43%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 1.12%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.29.
Analyst Recommendation Trends
Wall Street analyst consensus for MCK over the last few months:
Latest MCK News
3 Cash Rich US Stocks Investors Are Watching As Bond Yields Stay High
Bond yields have surged to levels not seen in decades, mortgage rates now sit above 7% and big institutional players are pulling back from Treasuries. That combination is reshaping how investors think about risk, cash flow and balance sheet strength. This piece walks through three large cap stocks exposed to these rate moves, all filtered for solid free cash flow, to help you judge which stories might deserve a closer look now. The three examples below are only a sample set, and the full...
Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDex
Medical-dental supplies see durable demand from specialty care, AI and aging trends, with McKesson and peers navigating tariffs and inflation.
Company News for Oct 2, 2026
Companies In The News Are: ACN, AYI, MCK, PRGS.
Why McKesson Stock Soared More Than 5% Higher Today
The company extended its existing partnership with a major pharmacy chain.
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.
Why McKesson (MCK) Stock Is Trading Up Today
Shares of healthcare distributor and services company McKesson (NYSE:MCK) jumped 4.4% in the afternoon session after the company reached an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032.
Which S&P500 stocks are moving on Thursday?
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Stock Market Midday, Oct. 1: Stocks Edge Lower as Treasury Yields Surge to 24-Year High
Bond yields hit their highest level in two decades, pressuring blue chip dividend stocks and weighing on the broader market, today, Oct. 1, 2026.
McKesson extends CVS deal; shares rise
Investing.com -- McKesson Corporation (NYSE:MCK) shares rose 4.4% Thursday following the announcement of an extended pharmaceutical distribution agreement with CVS Health through June 2032.
These S&P500 stocks are gapping in today's session
Looking for the S&P500 stocks that are experiencing notable gaps on Thursday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.
EPIC Rx Introduces New Wholesale Distribution Options for Member Pharmacies
RICHMOND, Va., October 01, 2026--EPIC Pharmacies, Inc. (EPIC Rx), a nationwide buying group dedicated to supporting and empowering independent pharmacies, today announced an expanded approach to wholesale distribution that provides member pharmacies with greater choice and flexibility in how they purchase medications. As a champion of pharmacy independence, EPIC Rx is putting greater control in the hands of pharmacy owners and operators, allowing them to select the wholesale partner that best al
McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
IRVING, Texas, October 01, 2026--McKesson Corporation (NYSE: MCK) announced today that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies, and distribution centers through June 2032.
Cardinal Health, McKesson Double Down on CVS Deals Through 2032
Cardinal Health and McKesson extend drug distribution deals with CVS Health through June 2032, reaffirming FY2027 adjusted earnings guidance.
5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve
Here, we highlight five medical supplies stocks, MCK, CAH, BDX, MMSI and PDEX, with strong potential that investors should keep on their watchlist amid improving industry prospects.
McKesson Reiterates FY27 Adjusted EPS Outlook Range Of $44.20 To $45
McKesson Corporation (NYSE: MCK) announced today it is reaffirming its fiscal year 2027 adjusted EPS guidance of $44.20 to $45.00 and its long-term adjusted EPS growth rate of 13% to 16%. Further updates will be
McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
McKesson (MCK) reached $853.81 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.
Cardinal Health: I'm Still Buying After Checking The Numbers
Cardinal Health remains a Buy, driven by robust FY2026 results, strong cash flow, and credible FY2027 guidance. Read more on CAH stock here.
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson's specialty distribution, oncology and GLP-1 growth are driving earnings, while drug pricing, margin pressure and policy uncertainty pose challenges.
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.
Dividend Champion, Contender, And Challenger Highlights: Week September 27
Get the weekly summary of dividend changes for Dividend Champions, Contenders & Challengers, plus upcoming ex-dividend and pay dates.
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.
McKesson (MCK) Lifted Its Guidance, Is The Stock Still 11% Undervalued?
McKesson (MCK) is back in focus after its share price dipped 1.2%, trailing the broader market, as investors weigh mixed earnings estimates against the company’s raised full-year adjusted EPS guidance and specialty-led healthcare footprint. Recent trading has been choppy for McKesson, with the share price slipping 3.95% over the past 30 days even after a 13.86% 90 day share price return and a 5.58% share price gain year to date. That near term hesitation sits against a much stronger backdrop,...
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.
Cardinal Health vs. McKesson: Which Healthcare Stock Is Better?
CAH's specialty-led growth, stronger EPS outlook and improving estimate momentum set up a compelling case against MCK.
Here’s How Much You Would Have Made Owning McKesson Stock In The Last 5 Years
McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 22.21% on an annualized basis producing an average annual return of 34.23%. Currently, McKesson has a market capitalization of $102.91 billion.
Why McKesson (MCK) Dipped More Than Broader Market Today
The latest trading day saw McKesson (MCK) settling at $880.5, representing a -1.2% change from its previous close.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release Date
IRVING, Texas, September 23, 2026--McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2027 financial results after market close on Wednesday, November 4, 2026. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.
Can CAH's MSO Expansion Unlock Growth in Specialty Care Delivery?
CAH is expanding its MSO strategy across specialty care, with Solaris and broader services aimed at scaling physician networks.
3 Reasons MCK Has Explosive Upside Potential
Since March 2026, McKesson has been in a holding pattern, floating around $872.99. The stock also fell short of the S&P 500’s 16.4% gain during that period.
Really like Northrop Grumman as a value play, says Regan Capital's Skyler Weinand
Skyler Weinand, Regan Capital CIO, joins 'Power Lunch' to discuss the best stocks for a sustained rate hike cycle.
1 Unpopular Stock That Deserves Some Love and 2 We Turn Down
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Alluvium Raised Its McKesson (MCK) Stake as Long-Term Growth Expectations Remain Strong
Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined […]
Did McKesson’s (MCK) EPS Hike and Oncology Push Just Redefine Its Investment Narrative?
McKesson recently raised its full-year EPS guidance, projecting approximately 13%–15% growth (15%–17% excluding certain prior-year items), and outlined plans to rebrand its Medical-Surgical unit as Wellverse with a potential IPO targeted for the second half of 2027, alongside a pending acquisition of Precision Medicine Group to expand oncology and biopharma-services capabilities, subject to regulatory approval. This combination of upgraded earnings expectations, portfolio reshaping around...
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal
McKesson (NYSE:MCK) executives said the company’s first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions businesses. Speaking at the Morgan Stanl
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.
McKesson Corporation (MCK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
McKesson Corporation (MCK) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 7:45 AM EDTCompany ParticipantsBrian Tyler - CEO &...
RBC Capital Reiterates Sector Perform on McKesson, Maintains $845 Price Target
RBC Capital analyst Ryan Halsted reiterates McKesson (NYSE:MCK) with a Sector Perform and maintains $845 price target.
CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?
Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.
McKesson (MCK) Suffers a Larger Drop Than the General Market: Key Insights
McKesson (MCK) closed at $880.86 in the latest trading session, marking a -1.21% move from the prior day.
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue?
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Janus Henderson Global Sustainable Equity (ADR) Managed Account Q2 2026 Portfolio Update
The largest positive contributors included Seagate, Micron, and Taiwan Semiconductor. Read more here.
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Frazier Healthcare Partners Welcomes Tom Rodgers as Senior Partner
SEATTLE, September 09, 2026--Frazier Healthcare Partners, a private equity firm focused exclusively on the healthcare industry, is pleased to announce that Tom Rodgers will join the firm as a Senior Partner in October 2026. In this role, Mr. Rodgers will partner with Frazier’s Growth Buyout deal teams, providing strategic counsel on investment evaluation, portfolio value creation, and sector-level insights informed by more than 35 years of experience in healthcare strategy, corporate development
3 Market-Beating Stocks for Long-Term Investors
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates
McKesson (NYSE:MCK) discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter. The company said Precision Medicine Group would expand two areas it has id
Reliant Infusion Names Tommy Pourmahram Chief Executive Officer
CHICAGO, September 08, 2026--Shore Capital Partners ("Shore" or "Shore Capital"), a Chicago-based private equity firm with an office in Nashville, today announced that Tommy Pourmahram has been named Chief Executive Officer of Reliant Infusion, a Shore portfolio company and provider of specialty infusion services.
McKesson Corporation (MCK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
McKesson Corporation (MCK) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 8:00 AM EDTCompany ParticipantsKenny Cheung - Executive VP &...
Underestimating The Moat: Why McKesson's Oncology Pivot And Share Buybacks Signal Structural Upside
McKesson operates within a US pharma distribution oligopoly, generating $5B+ in FCF and aggressively repurchasing shares. See why I rate MCK stock a Buy.
Here's How CVS Is Focusing on Aetna's Profitability Turnaround
CVS Health is advancing Aetna's profitability turnaround, supported by stronger Health Care Benefits results, an improved MBR and operational initiatives.
McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy
Reuters reported that McKesson Corporation (NYSE:MCK) said it would buy privately held Precision Medicine Group in a deal valued at about $2.25 billion as part of a “years-long effort to strengthen its higher-growth businesses.” McKesson has been reshaping its portfolio by exiting non-core assets and streamlining its operations while investing in businesses such as oncology […]
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Why Is McKesson (MCK) Up 5.7% Since Last Earnings Report?
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
McKesson Stock: Is MCK Outperforming the Healthcare Sector?
McKesson has outpaced the healthcare sector, and analysts remain highly optimistic about the stock’s outlook.
A Congress Member Sold Up To $15K In Viasat Stock: Here's What You Need To Know
A September filing shows that Representative Jonathan Jackson reported a sale in Viasat (NASDAQ:VSAT), valued between $1,001 and $15,000. The transaction date is listed as August 28, 2026, with the report published on
Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”
On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his “absolute favorites” and mentioned its growing exposure to specialty pharmaceuticals and higher-margin healthcare services. Cardinal’s been running circles around McKesson and Cencora. They consistently put up the best numbers because this company has gradually become less of […]
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
Is Generics Still a Quiet Profit Engine for Cardinal Health?
Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-08 | Rutledge Napoleon B JR | -111 | $891.45 | $98,951 |
| 2026-08-10 | Lerman Bradley E | -301 | $892.325 | $268,590 |
| 2026-08-07 | Srinivasan Ramesh (NMN) | +368 | - | - |
| 2026-07-22 | Hinton James H. | +277 | - | - |
| 2026-07-22 | Doughtie Lynne M | +277 | - | - |
| 2026-07-22 | Gerberding Julie L. | +277 | - | - |
| 2026-07-22 | Martinez Maria | +277 | $814.04 | $225,489 |
| 2026-07-22 | Lerman Bradley E | +277 | - | - |
| 2026-07-22 | OZAN KEVIN M | +277 | - | - |
| 2026-07-22 | Caruso Dominic J | +277 | $814.04 | $225,489 |
| 2026-07-22 | Dunsire Deborah | +277 | - | - |
| 2026-07-22 | Wilson-Thompson Kathleen | +277 | $814.04 | $225,489 |
| 2026-07-22 | Dunbar Webster Roy | +277 | - | - |
| 2026-07-07 | TYLER BRIAN S. | -8,463 | $793.56 | $6,715,898 |
| 2026-06-17 | TYLER BRIAN S. | -8,463 | $775.13 | $6,559,925 |
| 2026-06-09 | TYLER BRIAN S. | -4,929 | $763 | $3,760,827 |
| 2026-06-05 | Rutledge Napoleon B JR | -133 | $764 | $101,612 |
| 2026-06-02 | Rodgers Thomas L | -699 | $735.27 | $513,954 |
| 2026-06-01 | Rodgers Thomas L | -123 | $735.5 | $90,467 |
| 2026-06-01 | Smith LeAnn B | -1,810 | $735.5 | $1,331,255 |
| 2026-05-29 | Cheung Kenny K | +3,019 | - | - |
| 2026-05-29 | Cheung Kenny K | +8,082 | - | - |
| 2026-05-26 | Lau Michele | -3,550 | $761.09 | $2,701,870 |
| 2026-05-26 | Rodgers Thomas L | -2,388 | $761.09 | $1,817,483 |
| 2026-05-23 | Fraga Francisco | -136 | - | - |
| 2026-05-23 | Fraga Francisco | -54 | $766.08 | $41,368 |
| 2026-05-23 | Fraga Francisco | +136 | - | - |
| 2026-05-23 | Smith LeAnn B | -679 | - | - |
| 2026-05-23 | Smith LeAnn B | -268 | $766.08 | $205,309 |
| 2026-05-23 | Smith LeAnn B | +679 | - | - |
| 2026-05-23 | Rutledge Napoleon B JR | -136 | - | - |
| 2026-05-23 | Rutledge Napoleon B JR | -41 | $766.08 | $31,409 |
| 2026-05-23 | Rutledge Napoleon B JR | +136 | - | - |
| 2026-05-23 | Rodgers Thomas L | -594 | - | - |
| 2026-05-23 | Rodgers Thomas L | -234 | $766.08 | $179,263 |
| 2026-05-23 | Rodgers Thomas L | +594 | - | - |
| 2026-05-23 | Vitalone Britt J. | -1,476 | - | - |
| 2026-05-23 | Vitalone Britt J. | -581 | $766.08 | $445,092 |
| 2026-05-23 | Vitalone Britt J. | +1,476 | - | - |
| 2026-05-23 | TYLER BRIAN S. | -4,579 | - | - |
| 2026-05-23 | TYLER BRIAN S. | -1,831 | $766.08 | $1,402,692 |
| 2026-05-23 | TYLER BRIAN S. | +4,579 | - | - |
| 2026-05-21 | Fraga Francisco | -483 | - | - |
| 2026-05-21 | Fraga Francisco | -191 | $766.5 | $146,402 |
| 2026-05-21 | Fraga Francisco | +483 | - | - |
| 2026-05-21 | Smith LeAnn B | -531 | - | - |
| 2026-05-21 | Smith LeAnn B | -209 | $766.5 | $160,199 |
| 2026-05-21 | Smith LeAnn B | +531 | - | - |
| 2026-05-21 | Lau Michele | -724 | - | - |
| 2026-05-21 | Lau Michele | -285 | $766.5 | $218,453 |
| 2026-05-21 | Lau Michele | +724 | - | - |
| 2026-05-21 | Rutledge Napoleon B JR | -91 | - | - |
| 2026-05-21 | Rutledge Napoleon B JR | -27 | $766.5 | $20,696 |
| 2026-05-21 | Rutledge Napoleon B JR | +91 | - | - |
| 2026-05-21 | Rodgers Thomas L | -423 | - | - |
| 2026-05-21 | Rodgers Thomas L | -157 | $766.5 | $120,341 |
| 2026-05-21 | Rodgers Thomas L | +423 | - | - |
| 2026-05-21 | Vitalone Britt J. | -1,207 | - | - |
| 2026-05-21 | Vitalone Britt J. | -447 | $766.5 | $342,626 |
| 2026-05-21 | Vitalone Britt J. | +1,207 | - | - |
| 2026-05-21 | TYLER BRIAN S. | -3,500 | - | - |
| 2026-05-21 | TYLER BRIAN S. | -1,319 | $766.5 | $1,011,014 |
| 2026-05-21 | TYLER BRIAN S. | +3,500 | - | - |
| 2026-05-20 | Fraga Francisco | -463 | - | - |
| 2026-05-20 | Fraga Francisco | -183 | $754.68 | $138,106 |
| 2026-05-20 | Fraga Francisco | +463 | - | - |
| 2026-05-20 | Smith LeAnn B | -463 | - | - |
| 2026-05-20 | Smith LeAnn B | -183 | $754.68 | $138,106 |
| 2026-05-20 | Smith LeAnn B | +463 | - | - |
| 2026-05-20 | Lau Michele | -677 | - | - |
| 2026-05-20 | Lau Michele | -267 | $754.68 | $201,500 |
| 2026-05-20 | Lau Michele | +677 | - | - |
| 2026-05-20 | Rutledge Napoleon B JR | -74 | - | - |
| 2026-05-20 | Rutledge Napoleon B JR | -22 | $754.68 | $16,603 |
| 2026-05-20 | Rutledge Napoleon B JR | +74 | - | - |
| 2026-05-20 | Rodgers Thomas L | -324 | - | - |
| 2026-05-20 | Rodgers Thomas L | -128 | $754.68 | $96,599 |
| 2026-05-20 | Rodgers Thomas L | +324 | - | - |
| 2026-05-20 | Vitalone Britt J. | -1,038 | - | - |
| 2026-05-20 | Vitalone Britt J. | -409 | $754.68 | $308,664 |
| 2026-05-20 | Vitalone Britt J. | +1,038 | - | - |
| 2026-05-20 | TYLER BRIAN S. | -3,189 | - | - |
| 2026-05-20 | TYLER BRIAN S. | -1,282 | $754.68 | $967,500 |
| 2026-05-20 | TYLER BRIAN S. | +3,189 | - | - |
| 2026-05-19 | Fraga Francisco | +1,576 | - | - |
| 2026-05-19 | Fraga Francisco | -843 | $761.89 | $642,273 |
| 2026-05-19 | Fraga Francisco | +2,339 | - | - |
| 2026-05-19 | Fraga Francisco | -192 | $761.89 | $146,283 |
| 2026-05-19 | Fraga Francisco | +788 | - | - |
| 2026-05-19 | Smith LeAnn B | +1,471 | - | - |
| 2026-05-19 | Smith LeAnn B | -1,523 | $761.89 | $1,160,358 |
| 2026-05-19 | Smith LeAnn B | +4,129 | - | - |
| 2026-05-19 | Lau Michele | +1,969 | - | - |
| 2026-05-19 | Lau Michele | -1,753 | $761.89 | $1,335,593 |
| 2026-05-19 | Lau Michele | +4,454 | - | - |
| 2026-05-19 | Rutledge Napoleon B JR | +211 | - | - |
| 2026-05-19 | Rutledge Napoleon B JR | -234 | $761.89 | $178,282 |
| 2026-05-19 | Rutledge Napoleon B JR | +788 | - | - |
| 2026-05-19 | Rodgers Thomas L | +919 | - | - |
| 2026-05-19 | Rodgers Thomas L | -1,226 | $761.89 | $934,077 |
| 2026-05-19 | Rodgers Thomas L | +3,614 | - | - |
| 2026-05-19 | Vitalone Britt J. | -3,338 | $761.89 | $2,543,189 |
| 2026-05-19 | Vitalone Britt J. | +8,979 | - | - |
| 2026-05-19 | TYLER BRIAN S. | +9,739 | - | - |
| 2026-05-19 | TYLER BRIAN S. | -10,937 | $761.89 | $8,332,791 |
| 2026-05-19 | TYLER BRIAN S. | +27,863 | - | - |
| 2026-03-02 | Lau Michele | -2,725 | $990 | $2,697,750 |
| 2026-02-19 | Martinez Maria | -349 | $939.865 | $328,013 |
| 2026-02-17 | Smith LeAnn B | -190 | $945 | $179,550 |
| 2026-02-11 | Lau Michele | -303 | $933.39 | $282,817 |
| 2026-02-10 | Smith LeAnn B | -508 | - | - |
| 2026-02-10 | Smith LeAnn B | -129 | $935.21 | $120,642 |
| 2026-02-10 | Smith LeAnn B | +508 | - | - |
| 2026-02-09 | Lau Michele | -758 | - | - |
| 2026-02-09 | Lau Michele | -3,990 | - | - |
| 2026-02-09 | Lau Michele | -299 | $962.32 | $287,734 |
| 2026-02-09 | Lau Michele | +758 | - | - |
| 2026-02-09 | Lau Michele | -1,421 | $962.32 | $1,367,457 |
| 2026-02-09 | Lau Michele | +3,990 | - | - |
| 2026-02-06 | Rutledge Napoleon B JR | -328 | $955 | $313,240 |
| 2026-01-05 | Rodgers Thomas L | -276 | $816.18 | $225,266 |
| 2025-11-07 | Rutledge Napoleon B JR | -329 | $861.63 | $283,476 |